Key result
In a real-world Tunisian cohort of patients with newly diagnosed HFrEF, the 1-year cardiovascular mortality was 18.1% and the 1-year rehospitalization rate was 42.2%.
Why the study?
Heart failure represents a major public health problem, but few data are available regarding this pathology in Tunisia.
Cohort (n=210)
No
Real-world management of newly diagnosed HFrEF in Tunisia shows suboptimal adherence to guideline-directed medical therapy, leading to high 1-year mortality and rehospitalization rates.
Adds Egyptian data on new-onset HFrEF; leaves open guideline conformity and prognosis.
BACKGROUND: Heart failure (HF) is a serious and frequent pathology. It represents a major public health problem. We have few data about this pathology in our country. The aim of our study is to determine the epidemiological, clinical, therapeutic, and prognostic characteristics of new-onset HF with reduced left ventricular ejection fraction (HFrEF) and to study the degree of conformity of the management of HF with international recommendations. RESULTS: Our study population includes 210 patients hospitalized for HFrEF newly diagnosed. The average age of our patients was 64 ± 12 years. A male predominance was noted with a sex ratio of 2.8. The main etiology of HF was ischemic heart disease noted in 97 patients (46.2%). The average LVEF is 33 ± 6%. The triple combination (angiotensin-converting enzyme inhibitors + beta blockers + Mineralocorticoid Receptor Antagonists) was prescribed in 75 patients (35.7%). The quadruple combination (angiotensin-converting enzyme inhibitors + beta blockers + Mineralocorticoid Receptor Antagonists + Sodium-Glucose Co-Transporter 2 inhibitors) was prescribed in 17 patients (8.1%). Myocardial revascularization was indicated in 97 patients (46.6%) and valve surgery was indicated in 49 patients (23.3%). Hospital mortality was 3.8% and at 1 year 18.1%. Among the 192 patients followed during the first year after discharge from hospital, 81 patients had to be re-hospitalized, i.e., a 1-year rehospitalization rate of 42.2%. CONCLUSIONS: Our study highlighted the epidemiological and clinical features of HF in a Tunisian care center, revealing our patient management deficiency. This pushes us to have a new Tunisian register to enable a better statistical analysis and lead to more relevant conclusions.
No takes yet. Share an insight, caveat, or question.
Drissa et al. (2023) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=210). Real-world management of HFrEF was evaluated on Occurrence of cardiac death and/or re-hospitalization for heart failure within 1 year. In a real-world Tunisian cohort of patients with newly diagnosed HFrEF, the 1-year cardiovascular mortality was 18.1% and the 1-year rehospitalization rate was 42.2%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: